Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 220
- Registration Number
- NCT00593255
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, Shanghai, China
Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 164
- Registration Number
- NCT00592969
- Locations
- 🇧🇷
Novo Nordisk Investigational Site, Santa Efigenia, Brazil
Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 132
- Registration Number
- NCT00592527
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Nagpur, India
Initiation of Insulin Aspart in Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6
- Registration Number
- NCT00572806
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, MONTPELLIER cedex 5, France
Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 61
- Registration Number
- NCT00571935
- Locations
- 🇵🇱
Novo Nordisk Investigational Site, Warszawa, Poland
High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors
Phase 4
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia B With InhibitorsHaemophilia A With Inhibitors
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT00571584
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Comparison of Glycemic Control Achieved With 2 Different Needles
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 1Delivery SystemsDiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 62
- Registration Number
- NCT00572052
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, San Antonio, Texas, United States
Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Delivery SystemsDiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 208
- Registration Number
- NCT00569998
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sidcup, United Kingdom
Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 241
- Registration Number
- NCT00569400
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Marikina City, Philippines
Evaluating the Use of Two Different Needles in Subjects With Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Delivery SystemsDiabetes
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 119
- Registration Number
- NCT00569426
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath